Novo Nordisk A/S (CPH:NOVO.B)
432.85
-5.75 (-1.31%)
May 14, 2025, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B
Revenue Growth
+24.11%
P/S Ratio
6.42
Revenue / Employee
3.92M
Employees
77,349
Market Cap
1,946.97B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coloplast | 27.79B |
Genmab | 21.64B |
Demant | 22.42B |
ALK-Abelló | 5.71B |
Zealand Pharma | 55.69M |
H. Lundbeck | 22.00B |
Ambu A/S | 5.83B |
GN Store Nord | 17.67B |
Novo Nordisk News
- 3 hours ago - Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
- 3 hours ago - Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
- 3 hours ago - Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
- 3 hours ago - This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent - MarketWatch
- 5 hours ago - Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - WSJ
- 5 hours ago - Novo Nordisk in pact with Septerna for oral obesity drugs - Seeking Alpha
- 5 hours ago - Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters
- 15 hours ago - Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - Seeking Alpha